Sagent Pharmaceuticals has acquired Omega Laboratories Limited, a specialty pharmaceutical company based in Montreal, Canada. Sagent acquired Omega for approximately US$85.3 million (C$95 million) in an all-cash deal.
Merck has completed the sale of its consumer care business, which makes products including...
Capsugel announced today that it has received EXCiPACT™ certification for its sites in Bornem,...
Ireland's Minister for Jobs, Enterprise & Innovation, Richard Bruton TD, today announced...
Under the terms of the contract, Jacobs is providing engineering, procurement and construction management services for a new purification pilot plant project, which initially involves one purification line. The project is expected to expand Novo Nordisk’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs in development.
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumor types.
The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial that targets the less-obvious sufferers of the sexual condition: women.
The companies said patients who took the drug, called dupilumab, and nasal corticosteroids had smaller nasal polyps following treatment. They said the drug helped the drug also helped improve patients' air flow and reduced symptoms like congestion and runny nose.
Bristol-Myers Squibb Company will settle $1.4B in pension obligations through the purchase of a group annuity contract from The Prudential Insurance Company of America for approximately 8,000 U.S. retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014.
Shares of some companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.
WuXi PharmaTech has acquired XenoBiotic Laboratories, Inc., a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.
From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed Tuesday in a new effort to spotlight potential ethical conflicts in medicine.
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The deal includes Alios' portfolio of potential therapeutics for viral infections.
Perrigo Company has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals.
Acknowledging strong public skepticism in Europe over free trade talks with the U.S., the European Union's incoming trade chief on Monday called for a "fresh start" and more transparency in the negotiations.
Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.
Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern's oncology and anti-infective offerings.
The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $75 million in stock on the privately held Lumara, which makes Makena, a treatment designed to reduce the risk of premature birth.
Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
Pfizer announced that it has completed its acquisition of pharmaceutical development company, InnoPharma, Inc., and Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American-branded generics pharmaceutical presence.
Chemists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped. They hope their findings will help to design drugs that could target the enzyme, known as NMT, and potentially lead to new treatments for cancer and inflammatory conditions.
Akorn, Inc. has broken ground on a project that will add 40,000 square feet to its plant. The company recently bought a neighboring property to accommodate the expansion, which includes remodeling and modernizing equipment as part of an $18 million effort to increase production.
Capsugel acquires Bend Research and Encap Drug Delivery to create a comprehensive solid dosage form solutions group.
The company creates DNA-based vaccines and immune therapies, and said its vaccine might be able to address a variety of developing strains of Ebola. Inovio said that it will work with GeneOne Life Science, a company in which Inovio owns a minority stake.
Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.
The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.
SAFC will contribute extensive expertise in conjugation and the manufacture of drug linkers, while BioPharma Solutions will offer world-class, sterile fill/finish services for final filling of ADC products.
Genzyme, a Sanofi company, today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness.
Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''
- Page 1